Back to Authors

van der Meer, Peter

0000-0002-9705-4413

Mayo Clinic

Department of Cardiology, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, Netherlands. p.van.der.meer@umcg.nl.

Citations 4

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

New England Journal of Medicine | August 30, 2024 | Volume: 392 | Issue: 1 | Pages: 33-44

10.1056/nejmoa2409134 | PMID 39213194

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

New England Journal of Medicine | March 28, 2024 | Volume: 390 | Issue: 15 | Pages: 1394-1407

10.1056/nejmoa2313917 | PMID 38587233

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

New England Journal of Medicine | August 25, 2023 | Volume: 389 | Issue: 12 | Pages: 1069-1084

10.1056/nejmoa2306963 | PMID 37622681

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH

Science Translational Medicine | November 8, 2017 | Volume: 9 | Issue: 415 | Pages: No page available

10.1126/scitranslmed.aam8574 | PMID 29118264

OPLAH is cardioprotective for myocardial infarction, and its substrate 5-oxoproline is a putative circulating marker for heart failure.